The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | PROSIT: prognostic signatures in stage II colon cancer in the TOSCA trial
Alberto Puccini, MD, Humanitas Research Hospital, Milan, Italy, discusses findings from the PROSIT study, which aimed to elucidate prognostic signature in patients with stage II colon cancer enrolled in the Phase III TOSCA trial (NCT00646607). In the trial, patients were randomized to receive three of six months of chemotherapy. A signature was identified among 17 differentially expressed genes independent of MSI status. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did this project with samples coming from the TOSCA trial, which is a Phase III randomized trial, analyzing the differences between three months and six months chemotherapy in adjuvant colon cancer. We did this analysis retrospectively and we did RNAseq to see in patient in stage II high risk. If we could find a signature in order to individuate and see whether the patients go back worse or better independently to all the well known prognostic factors...
We did this project with samples coming from the TOSCA trial, which is a Phase III randomized trial, analyzing the differences between three months and six months chemotherapy in adjuvant colon cancer. We did this analysis retrospectively and we did RNAseq to see in patient in stage II high risk. If we could find a signature in order to individuate and see whether the patients go back worse or better independently to all the well known prognostic factors. And indeed, we found a prognostic signature. We found the 17 differentially expressed genes. And this this signature clearly differentiated a group of two group of patients with worse prognosis and better prognosis independently to all our well-known biomarkers including MSI. So the hazard ratio for the prognostic signature is 3.5 is highly significant. And this is just the a previous the first data on this signature, we are going to validate in a larger and prospective cohort to see if actually this can be implemented in a clinical practice in the future.
Read more...
